US OptionsDetailed Quotes
ME250117C8000
- 0.10
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open0.10Pre Close0 Volume60 Open Interest8.00Strike Price0.00Turnover0.00%IV129.46%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma35.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
23andMe Stock Discussion
Sign in to post a comment
$23andMe (ME.US)$
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
16 seconds ago, 4:30 AM PST
Via GlobeNewswire
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class t...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
16 seconds ago, 4:30 AM PST
Via GlobeNewswire
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class t...
$23andMe (ME.US)$
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million
Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs
SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million
Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs
SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics...
13
1
1
No comment yet
MonkeyGee : holding tight